Common Sense for Drug Policy - Link to home page

Sunday, March 26, 2023
Search using CSDP's own search tool or use

WWW Common Sense

Home page

About CSDP

PSA Campaign

Check out these other CSDP news pages:
Anti-Drug Media Campaign
Asia and the US Drug War
Bush's Cabinet
Chronic Pain Management
Communities Against the Drug War
Conferences & Events
DARE Admits Failure
Drug Control Alternatives
Families Targeted by Drug War
Federal Drug Control Strategy
Hemp News
Heroin & Heroin Addiction Treatment
Higher Education Act (HEA) Reform
International Reform
Mandatory Minimums
Medical Marijuana
Narco-Funded Terrorism
New Mexico
New York
Pain Management
Police Shootings & Botched Raids
Prop 36
Racial Profiling
Recommended Reading
Research News
South America
Treatment Alternatives to Incarceration
United Kingdom Moves Toward Reform
United Nations: News and Reports

Drug War Facts

Research Archive

Coalition for Medical Marijuana

Managing Chronic Pain

Drug War Distortions

Safety First

Get Active!

Drug Truth Network


Drug Strategy

Drugs and Terror

Recommended Reading

Site Map

link to 
Drug War Facts - page opens in new window
in the Family

Online Drug Library

Research Resources

Contact Common Sense

Back to Medical Marijuana News
Home page

Cannabis Drug Available In The UK

BBC News, Nov. 15, 2005

Multiple sclerosis patients in the UK are to be able to get a cannabis-based pain-relief drug from their doctor for the first time, it has been announced.

Sativex has already been licensed for use in Canada to relieve pain in people with MS.

The Home Office has now said the drug can be imported to the UK for individual patient's use.

MS charities welcomed the development as a step towards the drug being fully licensed for use on the NHS.

Eighty-five thousand people in the UK have MS. It is not yet certain how many of them would benefit from Sativex.

The drug is a mouth spray containing two chemicals found in cannabis, tetrahydrocannabinol and cannabidiol.

The announcement is believed to be in response to enquiries to the Home Office from doctors and patients about access to the drug.

'Quality of life'

Under the new arrangements, the prescription of Sativex would only be permitted under Home Office licence.


Sativex can significantly reduce nerve pain in MS patients, a study has shown. Researchers at Liverpool's Walton Centre for Neurology and Neurosurgery compared the drug with a dummy version in a study of 66 patients. Dr Carolyn Young, who led the research which was published in the journal Neurology, said the drug was seen to reduce pain and sleep disturbance.

A doctor would have to take responsibility for the prescription of the unlicensed drug, which would have to be imported from Canada for that particular patient.

Primary care trusts could decide to fund the treatment on the NHS. Otherwise, the drug would cost patients approximately 4 a day.

The government has asked a watchdog, the Commission on Human Medicines, to monitor the safety of Sativex.

Mike O'Donovan, chief executive of the MS Society said the prescription of the drug was: "a move in the right direction".

He added: "We believe there is now good evidence that cannabis-derived medicine can relieve distressing symptoms like spasticity [stiffness and muscle spasms] and pain in MS.

"Many people do not find available treatments effective and will now have the opportunity to try a new drug which could significantly improve their quality of life.

"We very much hope it will not be long before it is licensed for NHS prescription."

Cannabis research

Chris Jones, chief executive of the MS Trust added: "We must, however, highlight that, as with any treatment to alleviate MS symptoms, those which work for some people may not for others.

"With this in mind, we are pleased that people with MS may now have the opportunity, in discussion with their doctors, to access this treatment safely and legally and find out for themselves whether it is beneficial."

In a statement, the MHRA has said it did not object to the importation of Sativex for use to relieve pain in MS patients, but said it must be informed if the product was intended to be used for any other condition.

It added: "Under current regulations, the MHRA may only refuse an application to import an unlicensed medicine into the UK to meet the needs of a particular patient if there are overriding concerns about the product's safety or quality.

"Lack of proven efficacy is not a ground for refusing the import."

The company which makes Sativex, GW Pharmaceuticals, has been seeking a UK licence for the drug since 2003.

It has been granted a licence to cultivate cannabis for medical research purposes in the UK. Plants are being grown at a secret location in the English countryside.

The company says it will continue to seek a full UK licence for the drug.

Shares GW Pharmaceuticals' have jumped by 20% since news of the Home Office announcement emerged.

Save This Page to

Home Drug War Facts Public Service
Managing Chronic Pain
Get Active About Common Sense Addict In
The Family
Effective Drug
Control Strategy
Drug War Distortions Recommended

copyright © 2000-2007, Common Sense for Drug Policy
Kevin B. Zeese, President -- Mike Gray, Chairman -- Robert E. Field, Co-Chairman -- Melvin R. Allen, Board Member -- Doug McVay, Director of Research & Editor
1377-C Spencer Ave., Lancaster, PA 17603
tel 717-299-0600 - fax 717-393-4953
Updated: Thursday, July 09, 2009   ~   Accessed: 5616 times
Email us